BenevolentAI (AMS:BAI) Full Year 2023 Results
Key Financial Results
- Net loss: UK£63.3m (loss narrowed by 61% from FY 2022).
- UK£0.54 loss per share (improved from UK£1.50 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BenevolentAI Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 68%. Earnings per share (EPS) also missed analyst estimates by 55%.
Looking ahead, revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Europe.
Performance of the market in the Netherlands.
The company's shares are up 3.6% from a week ago.
Risk Analysis
Before we wrap up, we've discovered 3 warning signs for BenevolentAI (1 is significant!) that you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if BenevolentAI might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTAM:BAI
BenevolentAI
Operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company.
Moderate with adequate balance sheet.
